drugset
drugset / Trial / NCT06508645

Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers

NCT06508645 ↗

Phase 1 Completed 33 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetics, and pharmacodynamics after intravenous DWP14012 injection in healthy volunteers

Timeline

Start
2022-01-10
Primary completion
2022-03-29
Completion
2022-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule — Intravenous

Indications

No indication recorded.